Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionCIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory AnalysisDownregulation of miR-301a-3p sensitizes pancreatic cancer cells to gemcitabine treatment via PTENNADPH Oxidases: Insights into Selected Functions and Mechanisms of Action in Cancer and Stem Cells.Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-ASEnhancing Drug Efficacy and Therapeutic Index through Cheminformatics-Based Selection of Small Molecule Binary Weapons That Improve Transporter-Mediated Targeting: A Cytotoxicity System Based on Gemcitabine.BIRC6 mediates imatinib resistance independently of Mcl-1.Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture.Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.The Wnt/β-catenin signaling pathway mechanism for pancreatic cancer chemoresistance in a three-dimensional cancer microenvironment.Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.MGDG extracted from spinach enhances the cytotoxicity of radiation in pancreatic cancer cells.Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.The need for effective pancreatic cancer detection and management: a biomarker-based strategy.The safety and efficacy of gemcitabine for the treatment of bladder cancer.Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.Dr Jekyll and Mr Hyde: a strange case of 5-ethynyl-2'-deoxyuridine and 5-ethynyl-2'-deoxycytidine.AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling.Chemoresistance in pancreatic cancer: Emerging conceptsInhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cellsMechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry.Opioid Tripeptides Hybridized with trans-1-Cinnamylpiperazine as Proliferation Inhibitors of Pancreatic Cancer Cells in Two- and Three-Dimensional in vitro Models.Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.In vitro anticancer properties of selected Eucalyptus species.Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.
P2860
Q24273350-C5A9A28B-426B-42CF-B75E-7AFB69FEB615Q27853345-C3695141-6D49-4EA1-8CD8-094C01DB61B8Q28550236-DE5149B9-5DA7-41CE-B728-395221D11F7CQ33623176-9A9F42CA-7331-46A7-8ED2-F4F213A88D7AQ33775852-3DAF322C-10BD-41B2-91D0-4F5E87E2E23FQ34537580-68F64F27-5282-4EC6-83B1-F96F6BC16620Q35176428-AB0CED2F-1F97-438B-93B6-20F364BE91BBQ35879525-5E8B1F48-3D53-4E4D-993A-5F7182E2858EQ35895894-A1D23FFB-5DED-48B9-9614-CB49DD7D86C1Q36278738-A7B214D8-2D93-4E24-95C1-80E8A59984B1Q36342657-E645A66D-1D3C-407D-A975-874ED691279EQ36375641-38536BAC-3CD3-4BBC-A15E-CE607CA499E3Q36984038-68F38338-75DB-4EF6-8A4E-6A97F21FD4E8Q36990233-030C20F5-A387-4B67-9CF6-49A0EB8B9099Q37392942-C29FCE7D-5580-40F7-B61F-795EFA3DF604Q37393508-9FCB4121-14DE-48BC-8C37-C21DB4A03925Q37413849-E3F05EE2-FDF1-4BEE-A3BE-C9994BAAFFB2Q37431673-54D8E4A8-8EEC-4B8D-98F0-6C2A9F2ED1EEQ37455222-4FEF2057-5E10-4937-85A2-013DF731FE2BQ37720259-43F8BB9F-DE7C-4AF0-A8A0-9080608BA326Q38591066-C70849BC-2A92-4B88-8A2B-0E045B558394Q38701535-44884661-9A71-4B1B-992E-4965CF8DFA9FQ38714521-945C1C58-021D-49CD-94CC-CDF86BB0836FQ38760434-097502EB-C0DD-47DA-A5F0-86B73EC458F5Q38799790-73D4D725-D3AF-4F35-B771-A9B8DD31F035Q38804384-0FA89494-8C0B-4E6C-8F76-747D2FEE39E0Q38805955-9B356EB5-BF64-4906-82B8-3B0E5710F827Q38847702-93777B6D-75AD-4EDB-98A4-169C2D72F008Q38945152-B013A039-F95B-4A03-BEAA-661A1B11AE63Q40590883-B967CD8A-0BBD-40BE-80B3-235CE59ABC43Q41363526-C1B42669-208B-44F7-A34F-EDB7A87250A6Q41709484-083DF206-64A5-4976-8769-20664AD13244Q42002078-C00C6C18-5F97-4601-9D95-F91B0C78BEEEQ42199704-18FC5152-D1B1-468E-B230-1486455B31A6Q42374193-1181E2E7-4D5F-4FA1-8BBB-F8FD2858AF31Q44348324-B3C9394D-360F-491F-A8C7-1C288591F04FQ45062589-90FFA779-632B-4181-8555-61003EEBECF4Q46268031-6A6CCDC9-DE4C-4D34-BF8E-F3A10F75455FQ46375260-2585C1DE-FEC0-4144-A132-EFEE9B23A73BQ47093550-05CC493F-AC52-4D8E-AAAB-B5B6348D28C3
P2860
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@ast
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@en
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@nl
type
label
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@ast
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@en
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@nl
prefLabel
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@ast
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@en
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@nl
P3181
P1476
Gemcitabine: metabolism and mo ...... esistance in pancreatic cancer
@en
P2093
Lucas de Sousa Cavalcante
P3181
P356
10.1016/J.EJPHAR.2014.07.041
P407
P577
2014-10-15T00:00:00Z